Full Press Release Details
Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set
DUBLIN , June 1, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021 . Medtronic will showcase clinically meaningful outcomes associated with the company's comprehensive product portfolio and future technologies, as well as customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.
Scientific Presentations The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing with an option to query presenters throughout the conference.
MiniMed™ 780G System Poster Presentations
Continuous Glucose Monitor
Extended Wear Infusion Set Poster Presentations
Automated Insulin Pump System Poster Presentations
Smart Insulin Pens
Medtronic Sponsored Events The following symposium and three workshops will feature detailed clinical trial data and discussions with Medtronic and independent speakers. Details are as follows:
| Chantal Mathieu, M.D., Ph.D. | The Role of Technology in Type 1 Diabetes Beyond the Pandemic |
| Ohad Cohen, M.D., director, medical affairs, Medtronic | The MiniMed™ 780G System: Real-Word Evidence from the First 4,000 Users |
| Goran Petrovski, M.D., MSc, Ph.D. | From MDI Therapy to Automated Insulin Delivery Systems: Clinical Evidence |
| Bruce A. Buckingham, M.D. | Innovation in Infusion Sets: Extending the Wear for a Better Experience |
| David Dunleavy, vice president, portfolio management, Medtronic | Looking Toward the Future: Next Steps in the Advancement of Closing the Loop |
| Giovanni Annuzzi, M.D. | The Remote Onboarding Program: A Physician Point of View |
| Lutgarda Bozzetto, M.D., Ph.D. | Outcomes Achieved with Remote Onboarding |
| Ohad Cohen, M.D. Lutgarda Bozzetto, M.D., Ph.D. Mauro Cammarosano, senior training therapy specialist, Medtronic | Opportunities and Challenges of a Remote Onboarding |
| Natalie García Heil, patient onboarding program manager, Medtronic | Remote Onboarding: Tools, Resources and Patients' Feedback |
| Rainer Strassburger-Lausen, senior education program manager, Medtronic | Practical Session 1: Preparation of A Remote Training |
| Rainer Strassburger-Lausen | Practical Session 2: Using MiniMed™ 780G Virtual Demonstration in Remote Training |
| Andrew Rhinehart, M.D., senior medical director, Medtronic | Real World Evidence Review |
| Janice MacLeod | Introducing the Smart Insulin Pen Device |
| Janice MacLeod | Introducing the Integrated Smart Diabetes Management App |
| Anders Carlson, M.D. | Introducing Smart MDI Therapy and Overview of the Integrated Insights by InPen™ Data Reports |
About the Diabetes Business at Medtronic ( www.medtronicdiabetes.com ) Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
| Contacts: | |
| Kendra Cassillo | Ryan Weispfenning |
| Public Relations | Investor Relations |
| +1-818-576-5611 | +1-763-505-4626 |
SOURCE Medtronic plc